Hypoxia-informed RBE-weighted Beam Orientation Optimization for Intensity Modulated Proton Therapy

Overview

Journal Med Phys

Specialty Biophysics

Date 2024 Feb 12

PMID 38345134

Authors

Pavitra Ramesh

Dan Ruan

S John Liu

Youngho Seo

Steve Braunstein

Ke Sheng

Affiliations

Soon will be listed here.

Abstract

Background: Variable relative biological effectiveness (RBE) models in treatment planning have been proposed to optimize the therapeutic ratio of proton therapy. It has been reported that proton RBE decreases with increasing tumor oxygen level, offering an opportunity to address hypoxia-related radioresistance with RBE-weighted optimization.

Purpose: Here, we obtain a voxel-level estimation of partial oxygen pressure to weigh RBE values in a single biologically informed beam orientation optimization (BOO) algorithm.

Methods: Three glioblastoma patients with [ F]-fluoromisonidazole (FMISO)-PET/CT images were selected from the institutional database. Oxygen values were derived from tracer uptake using a nonlinear least squares curve fitting. McNamara RBE, calculated from proton dose, was then weighed using oxygen enhancement ratios (OER) for each voxel and incorporated into the dose fidelity term of the BOO algorithm. The nonlinear optimization problem was solved using a split-Bregman approach, with FISTA as the solver. The proposed hypoxia informed RBE-weighted method (HypRBE) was compared to dose fidelity terms using the constant RBE of 1.1 (cRBE) and the normoxic McNamara RBE model (RegRBE). Tumor homogeneity index (HI), maximum biological dose (Dmax), and D95%, as well as OAR therapeutic index (TI = gEUD /gEUD ) were evaluated along with worst-case statistics after normalization to normal tissue isotoxicity.

Results: Compared to [cRBE, RegRBE], HypRBE increased tumor HI, Dmax, and D95% across all plans by on average [31.3%, 31.8%], [48.6%, 27.1%], and [50.4%, 23.8%], respectively. In the worst-case scenario, the parameters increase on average by [12.5%, 14.7%], [7.3%,-8.9%], and [22.3%, 2.1%]. Despite increased OAR Dmean and Dmax by [8.0%, 3.0%] and [13.1%, -0.1%], HypRBE increased average TI by [22.0%, 21.1%]. Worst-case OAR Dmean, Dmax, and TI worsened by [17.9%, 4.3%], [24.5%, -1.2%], and [9.6%, 10.5%], but in the best cases, HypRBE escalates tumor coverage significantly without compromising OAR dose, increasing the therapeutic ratio.

Conclusions: We have developed an optimization algorithm whose dose fidelity term accounts for hypoxia-informed RBE values. We have shown that HypRBE selects bE:\Alok\aaeams better suited to deliver high physical dose to low RBE, hypoxic tumor regions while sparing the radiosensitive normal tissue.

References

Wright P, Rothe Arnesen M, Lonne P, Suilamo S, Silvoniemi A, Dale E . Repeatability of hypoxia dose painting by numbers based on EF5-PET in head and neck cancer. Acta Oncol. 2021; 60(11):1386-1391. DOI: 10.1080/0284186X.2021.1944663. View

Toffoli S, Michiels C . Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J. 2008; 275(12):2991-3002. DOI: 10.1111/j.1742-4658.2008.06454.x. View

Chan C, Chen F, Hsiao Y . Impact of Hypoxia on Relative Biological Effectiveness and Oxygen Enhancement Ratio for a 62-MeV Therapeutic Proton Beam. Cancers (Basel). 2021; 13(12). PMC: 8232608. DOI: 10.3390/cancers13122997. View

Henjum H, Dahle T, Mairani A, Pilskog S, Stokkevag C, Boer C . Combined RBE and OER optimization in proton therapy with FLUKA based on EF5-PET. J Appl Clin Med Phys. 2023; 24(9):e14014. PMC: 10476997. DOI: 10.1002/acm2.14014. View

Zhang W, Li W, Lin Y, Wang F, Chen R, Gao H . TVL1-IMPT: Optimization of Peak-to-Valley Dose Ratio Via Joint Total-Variation and L1 Dose Regularization for Spatially Fractionated Pencil-Beam-Scanning Proton Therapy. Int J Radiat Oncol Biol Phys. 2022; 115(3):768-778. PMC: 10155885. DOI: 10.1016/j.ijrobp.2022.09.064. View

Raju M, Amols H, Bain E, Carpenter S, Cox R, Robertson J . A heavy particle comparative study. Part III: OER and RBE. Br J Radiol. 1978; 51(609):712-9. DOI: 10.1259/0007-1285-51-609-712. View

Ma J, Tseung H, Courneyea L, Beltran C, Herman M, Remmes N . Robust radiobiological optimization of ion beam therapy utilizing Monte Carlo and microdosimetric kinetic model. Phys Med Biol. 2020; 65(15):155020. DOI: 10.1088/1361-6560/aba08b. View

Zindler J, Thomas Jr C, Hahn S, Hoffmann A, Troost E, Lambin P . Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription. J Natl Cancer Inst. 2015; 108(2). DOI: 10.1093/jnci/djv305. View

Ramesh P, Gu W, Ruan D, Sheng K . Dose and dose rate objectives in Bragg peak and shoot-through beam orientation optimization for FLASH proton therapy. Med Phys. 2022; 49(12):7826-7837. PMC: 9829523. DOI: 10.1002/mp.16009. View

10.

Evans S, Du K, Chalian A, Mick R, Zhang P, Hahn S . Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys. 2007; 69(4):1024-31. PMC: 2737259. DOI: 10.1016/j.ijrobp.2007.04.067. View

11.

McNamara L A, Willers H, Paganetti H . Modelling variable proton relative biological effectiveness for treatment planning. Br J Radiol. 2019; 93(1107):20190334. PMC: 7066955. DOI: 10.1259/bjr.20190334. View

12.

Alizadeh E, Orlando T, Sanche L . Biomolecular damage induced by ionizing radiation: the direct and indirect effects of low-energy electrons on DNA. Annu Rev Phys Chem. 2015; 66:379-98. DOI: 10.1146/annurev-physchem-040513-103605. View

13.

Tinganelli W, Durante M . Carbon Ion Radiobiology. Cancers (Basel). 2020; 12(10). PMC: 7603235. DOI: 10.3390/cancers12103022. View

14.

Chvetsov A, Hanin L, Stewart R, Zeng J, Rengan R, Lo S . Tumor control probability in hypofractionated radiotherapy as a function of total and hypoxic tumor volumes. Phys Med Biol. 2021; 66(12). DOI: 10.1088/1361-6560/ac047e. View

15.

Busk M, Overgaard J, Horsman M . Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions. Semin Nucl Med. 2020; 50(6):562-583. DOI: 10.1053/j.semnuclmed.2020.05.003. View

16.

Rorvik E, Fjaera L, Dahle T, Dale J, Engeseth G, Stokkevag C . Exploration and application of phenomenological RBE models for proton therapy. Phys Med Biol. 2018; 63(18):185013. DOI: 10.1088/1361-6560/aad9db. View

17.

Coleman C . Hypoxic cell radiosensitizers: expectations and progress in drug development. Int J Radiat Oncol Biol Phys. 1985; 11(2):323-9. DOI: 10.1016/0360-3016(85)90154-3. View

18.

Wenzl T, Wilkens J . Theoretical analysis of the dose dependence of the oxygen enhancement ratio and its relevance for clinical applications. Radiat Oncol. 2011; 6:171. PMC: 3283483. DOI: 10.1186/1748-717X-6-171. View

19.

Mapelli P, Picchio M . 18F-FAZA PET imaging in tumor hypoxia: A focus on high-grade glioma. Int J Biol Markers. 2020; 35(1_suppl):42-46. DOI: 10.1177/1724600820905715. View

20.

Dahle T, Rusten E, Stokkevag C, Silvoniemi A, Mairani A, Fjaera L . The FLUKA Monte Carlo code coupled with an OER model for biologically weighted dose calculations in proton therapy of hypoxic tumors. Phys Med. 2020; 76:166-172. DOI: 10.1016/j.ejmp.2020.07.003. View